Trastuzumab and Gefitinib in Treating Patients With Metastatic Breast Cancer

This study has been completed.

Study NCT00024154 Information provided by National Cancer Institute (NCI)

First Received: September 13, 2001 Last Updated: February 6, 2009 History of Changes

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Study Status:	This study has been completed.
Estimated Study Completion Date:	No date given
Primary Completion Date:	July 2007 (Final data collection date for primary outcome measure)

Publications:

Arteaga CL, O'Neill A, Moulder SL, Pins M, Sparano JA, Sledge GW, Davidson NE. A phase I-II study of combined blockade of the ErbB receptor network with trastuzumab and gefitinib in patients with HER2 (ErbB2)-overexpressing metastatic breast cancer. Clin Cancer Res. 2008 Oct 1;14(19):6277-83.

Moulder SL, O'Neill A, Arteaga C, et al.: Final results of ECOG1100: a phase I/II study of combined blockade of the ErbB receptor network in patients with HER2- overexpressing metastatic breast cancer (MBC). [Abstract] J Clin Oncol 25 (Suppl 18): A-1033, 2007.

Arteaga CL, O'Neil A, Moulder SL, et al.: ECOG-1100: a phase I-II study of combined blockade of the erbB receptor network with trastuzmab and gefitinib ([Isquo]Iressa) in patients (pts) with HER2-overexpressing metastatic breast cancer. [Abstract] Breast Cancer Res Treat 88 (Suppl 1): A-25, 2004.

[No authors listed] ECOG E1100: a phase II trial of trastuzumab and gefitinib in patients with metastatic breast cancer that overexpress HER2/neu (erbB-2). Clin Adv Hematol Oncol. 2003 Apr;1(4):237. No abstract available.